Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Rating of “Hold” by Brokerages

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been assigned a consensus recommendation of “Hold” from the twenty-two ratings firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $107.50.

ZBH has been the subject of several analyst reports. Baird R W downgraded Zimmer Biomet from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 16th. Rothschild & Co Redburn initiated coverage on Zimmer Biomet in a report on Thursday, September 18th. They set a “buy” rating and a $130.00 price objective on the stock. UBS Group reduced their price objective on shares of Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a research note on Thursday, November 6th. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. Finally, Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a report on Thursday, September 18th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Brighton Jones LLC purchased a new stake in Zimmer Biomet in the 4th quarter worth about $204,000. Brooklyn Investment Group increased its holdings in shares of Zimmer Biomet by 45.9% in the 1st quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 145 shares during the period. Wellington Management Group LLP lifted its position in shares of Zimmer Biomet by 230.6% in the first quarter. Wellington Management Group LLP now owns 36,865 shares of the medical equipment provider’s stock worth $4,172,000 after purchasing an additional 25,713 shares in the last quarter. Summit Financial LLC boosted its holdings in shares of Zimmer Biomet by 11.8% during the first quarter. Summit Financial LLC now owns 2,151 shares of the medical equipment provider’s stock worth $244,000 after purchasing an additional 227 shares during the period. Finally, CW Advisors LLC grew its position in Zimmer Biomet by 8.2% during the first quarter. CW Advisors LLC now owns 3,123 shares of the medical equipment provider’s stock valued at $353,000 after purchasing an additional 236 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Down 1.3%

ZBH stock opened at $89.25 on Friday. The firm has a market cap of $17.69 billion, a PE ratio of 22.09, a P/E/G ratio of 2.34 and a beta of 0.61. Zimmer Biomet has a 12 month low of $85.33 and a 12 month high of $114.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. The firm has a 50 day simple moving average of $94.96 and a 200 day simple moving average of $96.67.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same quarter in the previous year, the business posted $1.74 earnings per share. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, December 30th. Zimmer Biomet’s payout ratio is 23.76%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.